The development of patient-specific cardiac electrophysiology models represents a paradigm shift in cardiovascular medicine, moving away from population-averaged representations toward individualized computational replicas of the heart’s electrical function. These high-fidelity simulations incorporate a patient’s unique anatomy, tissue properties, and electrical wave propagation patterns, enabling clinicians to predict, diagnose, and treat complex arrhythmias with unprecedented precision. By bridging the gap between physiological theory and clinical practice, patient-specific cardiac models are transforming how we approach heart rhythm disorders, from pre-procedural planning to the design of novel therapeutic devices.

What Are Cardiac Electrophysiology Models?

Cardiac electrophysiology (EP) models are mathematical and computational representations of the electrical processes that govern the heart’s rhythmic beating. At their core, these models simulate the propagation of action potentials through myocardial tissue, capturing the dynamics of ion channels, cellular excitability, and tissue connectivity. The most detailed applications use either the bidomain model—which treats the intracellular and extracellular spaces as two interpenetrating domains—or its computationally efficient simplification, the monodomain model. These models are solved on patient-specific cardiac geometries derived from medical imaging, with local tissue conductivities, fiber orientations, and scar distribution assigned to match each individual’s physiology.

The key output of these simulations is a virtual representation of electrical activation and recovery across the heart. By altering parameters such as ionic current densities, gap junction conductance, or the presence of fibrotic tissue, researchers can recreate pathological patterns observed in clinical electrophysiological studies. This allows for the systematic exploration of how genetic mutations, pharmacological agents, or structural remodelling might alter arrhythmia initiation and maintenance in a specific patient.

Importance of Patient-Specific Models

Generic or template-based cardiac models offer a useful starting point for understanding basic electrophysiology, but they cannot account for the wide variability in human heart anatomy, myocardial architecture, and disease substrate. Patient-specific models address this gap by incorporating three critical sources of individual variation: anatomy (e.g., heart size, wall thickness, chamber morphology), tissue properties (e.g., scar burden, fibrosis pattern, fiber orientation), and electrical function (e.g., action potential duration restitution, conduction velocity).

This personalization dramatically improves the predictive accuracy of the simulations. For example, a patient with atrial fibrillation may have a markedly different left atrial geometry and fibrosis distribution compared to an age-matched control. A patient-specific model can reproduce the exact reentrant circuits that drive the arrhythmia, whereas a generic model might suggest circuits that do not exist. In the clinical setting, this translates to more reliable planning for catheter ablation, more accurate assessment of sudden cardiac death risk, and the ability to test therapeutic interventions in silico before applying them to the patient.

Beyond direct clinical applications, patient-specific models are a cornerstone of the broader precision medicine movement in cardiology. They enable a shift from “one-size-fits-all” protocols to tailored therapies that consider the unique biological substrate of each individual. This approach has already shown promise in improving outcomes for ventricular tachycardia ablation, cardiac resynchronization therapy optimization, and the prediction of drug-induced arrhythmias.

Development Process

Building a patient-specific cardiac EP model is a multi-step pipeline that integrates clinical data acquisition, image processing, computational geometry, mathematical modeling, and high-performance simulation. Each step must be executed with careful attention to accuracy and reproducibility.

Data Collection

Imaging: The foundation of any patient-specific model is high-resolution anatomical imaging. Magnetic resonance imaging (MRI) with late gadolinium enhancement (LGE) provides detailed three-dimensional reconstructions of the heart chambers and allows visualization of scar tissue. Cardiac computed tomography (CT) is often used for its superior resolution of the coronary arteries and epicardial surfaces, especially when planning epicardial ablation procedures. In some research protocols, diffusion tensor MRI (DT-MRI) is employed to map myocardial fiber orientation, which critically influences the anisotropic conduction of electrical signals.

Electrophysiological mapping: Clinical electroanatomic mapping systems (e.g., Carto, EnSite NavX, Rhythmia) record voltage, activation time, and local electrograms from hundreds of points on the endocardial or epicardial surface during catheterization. These data provide a ground-truth representation of the patient’s electrical activation pattern. When fused with the anatomical model, these maps serve as both a source of input parameters (e.g., tissue viability, local conduction velocity) and a benchmark for model validation.

Additional data sources: Patient-specific models may also incorporate serum electrolyte levels, genetic data (e.g., ion channel mutations linked to long QT syndrome), drug concentrations, and hemodynamic measurements. The integration of multi-modal data improves the physiological plausibility of the simulation and extends its predictive scope.

Model Construction

Mesh generation: The segmented imaging data (e.g., binary masks of blood pool, myocardium, scar) are converted into a finite element or finite volume mesh. The mesh must accurately represent the complex geometry of the endocardial and epicardial surfaces while maintaining sufficient resolution to capture the spatial gradients of the action potential. Adaptive meshing techniques are often employed to refine regions of high curvature or steep conduction gradients, such as near scar borders or the pulmonary veins.

Fiber orientation assignment: In the absence of DT-MRI data, rule-based algorithms can assign fiber angles based on known transmural variation (e.g., a helical fiber angle that rotates from -60° at the epicardium to +60° at the endocardium). More sophisticated approaches use statistical shape models or machine learning to predict fiber orientation from the patient’s anatomy, guided by a population-derived atlas.

Parameterization of tissue properties: Each element of the mesh is assigned a set of ionic model parameters (e.g., conductance of sodium, calcium, potassium channels) chosen to reproduce the measured action potential duration and restitution properties. For scar regions, conductivity may be set to zero (passive tissue) or modeled with a reduced conductance to mimic the slowing of conduction observed in border zones. Fibrotic tissue can be represented as a mixture of conductive and non-conductive elements at the subcellular level using the “mosaic” or “diffuse fibrosis” model.

Simulation and Analysis

Once the model is built, the electrical propagation is simulated by solving a system of partial differential equations that describe the conservation of current across the tissue. Intracellular and extracellular potentials, along with the ionic currents through the cell membrane, evolve over time. The simulation runtime depends heavily on the model’s spatial resolution and the complexity of the ionic model used, ranging from minutes (for simplified monodomain models with phenomenological ionic models) to days (for high-resolution bidomain models with detailed Markovian ion channel representations). High-performance computing clusters, cloud-based platforms, and GPU acceleration are now routinely employed to bring simulation times down to clinically relevant intervals—hours or even tens of minutes for a single steady-state beat.

Validation: A patient-specific model is only as useful as its accuracy. Validation is performed by comparing simulated activation maps or electrograms with those recorded during the clinical mapping procedure. Metrics such as the correlation coefficient of activation times, the root-mean-square error between simulated and measured unipolar electrograms, or the ability to reproduce pacing-induced arrhythmia circuits are used to adjust model parameters and ensure fidelity. In cases where validation reveals significant discrepancies, the model construction process may need to be revisited—for instance, by refining the mesh, revisiting scar segmentation, or adjusting the ionic model parameters.

Applications and Benefits

The clinical utility of patient-specific cardiac EP models spans diagnostic, therapeutic, and predictive domains. Below are the most prominent applications where these models have demonstrated their value.

Catheter Ablation Planning

Catheter ablation is a curative therapy for many arrhythmias, but success rates for complex substrates such as scar-related ventricular tachycardia (VT) and persistent atrial fibrillation remain suboptimal. Patient-specific models allow electrophysiologists to simulate the arrhythmia in silico and identify the critical isthmus or reentrant circuits responsible for maintenance. By performing virtual ablation on the model—removing a small set of elements—clinicians can predict where ablation lesions should be placed to terminate the arrhythmia while minimizing damage to healthy tissue. This approach has been shown to reduce ablation time, number of lesions, and recurrence rates in early clinical studies. For example, a 2021 study published in Circulation demonstrated that using patient-specific modeling to guide VT ablation led to a 40% reduction in arrhythmia recurrence at six months compared to standard substrate-based ablation.

Cardiac Resynchronization Therapy (CRT) Optimization

CRT is an established therapy for patients with heart failure and electrical dyssynchrony, yet 30–40% of recipients do not respond optimally. Patient-specific electrophysiology models integrated with mechanical contraction models (electromechanical models) can simulate the hemodynamic effect of different pacing lead positions and timing delays. By predicting the left ventricular activation pattern and its impact on stroke volume, these models enable clinicians to choose the optimal pacing configuration for the individual patient. Preliminary studies indicate that model-guided CRT optimization can increase the proportion of responders by 15–20%.

Pharmacological Risk Stratification

Drug-induced arrhythmias, particularly Torsades de Pointes, remain a major cause of drug attrition and post-market withdrawal. Patient-specific models can be used to simulate the effect of a drug on the action potential duration, taking into account the patient’s genetic background (e.g., long QT syndrome mutations), electrolyte levels, and baseline repolarization reserve. By running virtual drug trials on a cohort of patient-specific models, researchers can stratify risk for a new compound before human testing. The FDA and the international CIPA (Comprehensive in vitro Proarrhythmia Assay) initiative have endorsed such in silico approaches as part of a new paradigm for cardiotoxicity assessment.

Arrhythmia Risk Prediction in Inherited Channelopathies

For patients with Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), or hypertrophic cardiomyopathy, the risk of sudden cardiac death varies widely even among individuals with the same genetic mutation. Patient-specific models that incorporate the known cellular phenotype (e.g., reduced sodium current in Brugada syndrome) and the patient’s unique structural substrate can provide a personalized risk score. This score can help guide the decision to implant a defibrillator, calibrating the trade-off between the risk of inappropriate shocks and the risk of sudden death.

Challenges and Limitations

Despite rapid progress, several barriers prevent the widespread adoption of patient-specific EP models in routine clinical practice. The most significant challenges include acquisition and integration of high-quality data, computational cost, model uncertainty, and the need for rigorous validation in large, heterogeneous populations.

Data quality: The resolution and accuracy of clinical imaging and mapping data directly impact model fidelity. Low-quality MRI or mapping data with gaps in activation points can introduce artifacts that propagate through the model. Additionally, obtaining diffusion tensor imaging for fiber orientation is not yet part of routine clinical workflow, forcing reliance on rule-based or atlas-based fiber assignments that may not capture patient-specific variations.

Computational resources: High-fidelity simulations with bidomain models and detailed ionic kinetics on fine meshes require hours to days of computing time. While GPU acceleration and cloud computing are narrowing the gap, real-time “on the table” simulation during a procedure remains a distant goal. Hybrid approaches that use reduced-order models or machine learning surrogates may offer a pathway to clinically relevant turnaround times.

Model parameter uncertainty: Many parameters in the ionic models (e.g., intracellular conductivity, maximum channel conductances) cannot be measured directly in the patient. They are often estimated from literature or matched to global properties such as the QT interval. This introduces uncertainty, and small changes in these parameters can produce large variations in the simulated arrhythmia behavior. Bayesian inference and probabilistic modeling are being developed to quantify and propagate this uncertainty, but these methods add another layer of complexity.

Validation: Rigorous validation of patient-specific models requires high-density mapping data that is rarely available in clinical practice. Most validation studies rely on a limited number of endocardial points, which may not capture the full three-dimensional activation pattern. Moreover, the outcome of interest—whether the model predicted the optimal ablation strategy—can only be validated through follow-up, making iterative model refinement difficult during the initial procedure.

Future Directions

Looking ahead, patient-specific cardiac electrophysiology models are expected to evolve from offline research tools into integrated clinical decision support systems. Several promising avenues are being explored.

Artificial intelligence and surrogate modeling: Machine learning techniques, particularly deep learning and physics-informed neural networks, can learn the mapping from patient inputs to simulation outputs at a fraction of the computational cost. Once trained on a large dataset of patient-specific models, these surrogates could provide near-instant predictions of arrhythmia circuits or optimal ablation targets, making them suitable for intra-procedural use.

Digital twins of the heart: A digital twin is a dynamic, real-time digital replica of the patient’s organ that continuously assimilates data from wearable sensors, implantable devices, and electronic health records. For cardiac electrophysiology, a digital twin could update its parameters as the patient’s condition changes, enabling continuous risk monitoring and adaptive therapeutic strategies. Several European and US research consortiums are actively developing such frameworks, with early prototypes tested in pilot studies.

Integration with multi-scale models: Future models will increasingly link electrophysiology to mechanical contraction, valve function, and systemic hemodynamics within a single coupled framework. These electromechanical and fluid-structure interaction models will provide a more complete picture of the patient’s cardiac function, allowing clinicians to assess not only arrhythmia mechanisms but also their impact on pump function and symptoms.

Regulatory approval and clinical adoption: For patient-specific modeling to become a standard tool, regulatory bodies such as the FDA and EMA must establish clear guidelines for model qualification. The ASME V&V 40 standard for verification and validation of computational models in medical device development offers a starting point. Comparative effectiveness trials that demonstrate the clinical utility of model-guided care versus conventional care will be essential to justify the additional cost and time required to build the models.

Conclusion

Patient-specific cardiac electrophysiology models represent a powerful convergence of computational science, high-resolution clinical imaging, and electrophysiological mapping. By faithfully reproducing the electrical function of an individual’s heart, these models enable clinicians to plan ablation procedures with greater precision, optimize device therapy, screen drugs for proarrhythmic risk, and stratify patients for sudden cardiac death prevention. Although challenges related to data quality, computational cost, and validation remain, the rapid pace of technological innovation—especially in AI and high-performance computing—suggests that these barriers will soon be overcome. As the field matures, patient-specific electrophysiology models are poised to become a cornerstone of precision cardiology, transforming the management of heart rhythm disorders from reactive to truly predictive and personalized.

For further reading on the clinical implementation of patient-specific cardiac models, the National Heart, Lung, and Blood Institute provides an overview of funding initiatives and ongoing research networks. A comprehensive review of modeling techniques can be found in a recent article in Current Opinion in Biomedical Engineering.